PCG Digital

Recent News

  • Lexaria Bioscience Turns Focus to Dementia and Diabetes with New Studies

    New York, New York--(Newsfile Corp. - November 21, 2022) - PCG Digital -- Lexaria Bioscience (NASDAQ: LEXX) is investigating the potential therapeutic utility of its proprietary DehydraTECHTM-CBD against dementia and diabetes, two of the world's biggest public health crises.Lexaria BioscienceTo view an enhanced version of this graphic, please visit:

    2022-11-21 9:19 AM EST
  • Soligenix Enters Q4 With Multiple Catalysts in Play

    New York, New York--(Newsfile Corp. - October 13, 2022) - PCG Digital -- Late-stage biopharmaceutical company, Soligenix, Inc. (NASDAQ: SNGX) is anticipating significant catalysts in Q4 and a potentially transformational year in 2023.Following its successful Phase 3 clinical trial evaluating HyBryte (synthetic hypericin) as a treatment for cutaneous T-cell lymphoma (CTCL), Soligenix is preparing to file a New Drug Application (NDA) with the FDA. HyBryte™ will potentially be a first-in-class treatment for CTCL, a rare skin cancer.The company's Public Health...

    2022-10-13 8:30 AM EDT
  • Lexaria Bioscience: Taking Aim at the $28 Billion Hypertension Market; Human Clinical Study Yields 'Remarkable' Results

    New York, New York--(Newsfile Corp. - September 20, 2022) - PCG Digital - Lexaria Bioscience (NASDAQ: LEXX) (NASDAQ: LEXXW) is targeting the $28 billion hypertension drug market with its innovative drug delivery platform. Its proprietary therapeutic, DehydraTECH-CBD, offers an alternative to traditional cannabidiol (CBD) dosing methods, enabling improved and more rapid absorption of drugs into the bloodstream and brain.There is currently only one FDA approved CBD drug available on the market, used to treat pediatric epilepsy. Lexaria is positioned to...

    2022-09-20 8:30 AM EDT
  • FDA Awards $2.6 Million Grant for Expanded Study of Soligenix's Hybryte(TM) for CTCL

    New York, New York--(Newsfile Corp. - September 12, 2022) - PCG Digital -- Late-stage biopharmaceutical company Soligenix, Inc. (NASDAQ: SNGX) has announced the award of a $2.6 million grant from the FDA to support a study of expanded HyBryte™ treatment, including at-home usage. The FDA's support will give patients an opportunity to access Soligenix's HyBryte™ therapy in an open-label setting. HyBryte is a novel skin directed photodynamic therapy for cutaneous T-cell lymphoma (CTCL), a rare skin disease and cancer....

    2022-09-12 8:30 AM EDT
  • Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans

    New York, New York--(Newsfile Corp. - August 8, 2022) - PCG Digital -- Life may change for the better for the 10 million Americans suffering from fibromyalgia. The development-stage biotech Virios Therapeutics, Inc. (NASDAQ: VIRI) is anticipating the reporting of phase 2b treatment results for its lead fibromyalgia treatment candidate this September and continues to add value through its research and development of compelling clinical assets for multiple categories of viruses.

    2022-08-08 8:30 AM EDT
  • Soligenix's HyBryte(TM) Treatment Now Within Reach for Rare Cancer Patients

    New York, New York--(Newsfile Corp. - July 26, 2022) - PCG Digital -- Late-stage biopharmaceutical company, Soligenix, Inc. (NASDAQ: SNGX), has completed the largest placebo controlled, randomized Phase 3 trial ever done in cutaneous T-cell lymphoma (CTCL) evaluating a novel topical treatment for early-stage CTCL and is preparing to submit a New Drug Application to the FDA to commercialize the product.

    2022-07-26 9:27 AM EDT
  • Virios Therapeutics (Nasdaq: VIRI) Advancing Potential Paradigm Shift in Fibromyalgia Treatment

    New York, New York--(Newsfile Corp. - July 26, 2022) - PCG Digital -- Development-stage biotechnology company Virios Therapeutics (NASDAQ: VIRI) is working to advance a new therapeutic approach, one that is focused on addressing a potential root cause of Fibromyalgia (FM), a catalyst the company believes is related to activation of previously dormant herpes virus infection. VIRI is anticipating top line results this September from its ongoing FM Phase 2b trial, featuring its lead combination antiviral development candidate, oral...

    2022-07-26 8:30 AM EDT
  • Virios' Promising Fibromyalgia Treatment Candidate Expects September 2022 Phase 2b Results

    New York, New York--(Newsfile Corp. - July 19, 2022) - PCG Digital -- With the aim of improving the standard of care for the 10 million Americans living with fibromyalgia ("FM"), Virios Therapeutics (NASDAQ: VIRI) anticipates Phase 2b results for its lead treatment candidate, oral IMC-1, in September. Virios TherapeuticsTo view an enhanced version of this graphic, please

    2022-07-19 8:30 AM EDT